Role of the neurofibromatosis Type 2 gene in the development of tumors of the nervous system

Martin H. RuttledgeDepartment of Neurology, Kings College Hospital, London, United Kingdom; and Center for the Study of Brain Diseases, CHUM Research Center, Notre Dame Hospital, Montreal, Quebec, Canada

Search for other papers by Martin H. Ruttledge in
jns
Google Scholar
PubMed
Close
 M.B., B.Sc., Ph.D.
and
Guy A. RouleauDepartment of Neurology, Kings College Hospital, London, United Kingdom; and Center for the Study of Brain Diseases, CHUM Research Center, Notre Dame Hospital, Montreal, Quebec, Canada

Search for other papers by Guy A. Rouleau in
jns
Google Scholar
PubMed
Close
 M.D., Ph.D.
View More View Less
Full access

Germ line and somatic mutations in the neurofibromatosis Type 2 (NF2) tumor suppressor gene predispose individuals to tumors of the nervous system, including schwannomas and meningiomas. Since identification of the NF2 gene more than a decade ago, a large body of information has been collected on the nature and consequences of these alterations in patients with NF2 and in individuals in whom sporadic tumors associated with NF2 develop. The catalog of mutations identified thus far has facilitated extensive genetic analysis, including studies of patients with mosaicism and phenotype–genotype correlations, and has also led to experiments that have begun to unravel the molecular biology of the NF2 gene and its role in tumorigenesis. The authors describe some of the most significant findings in NF2 genetics and biology over the last decade.

Abbreviations used in this paper:

HRS = hepatocyte growth factor–regulated tyrosine kinase substrate; NF1, NF2 = neurofibromatosis Types 1 and 2; Pak1 = p21-activated kinase; PIKE = phosphatidylinositol 3–kinase enhancer; PI3K = phosphatidylinositol 3–kinase; VS = vestibular schwannoma.

Germ line and somatic mutations in the neurofibromatosis Type 2 (NF2) tumor suppressor gene predispose individuals to tumors of the nervous system, including schwannomas and meningiomas. Since identification of the NF2 gene more than a decade ago, a large body of information has been collected on the nature and consequences of these alterations in patients with NF2 and in individuals in whom sporadic tumors associated with NF2 develop. The catalog of mutations identified thus far has facilitated extensive genetic analysis, including studies of patients with mosaicism and phenotype–genotype correlations, and has also led to experiments that have begun to unravel the molecular biology of the NF2 gene and its role in tumorigenesis. The authors describe some of the most significant findings in NF2 genetics and biology over the last decade.

  • Collapse
  • Expand

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 403 44 1
PDF Downloads 331 68 2
EPUB Downloads 0 0 0